Design and in silico screening of inhibitors of the cholera toxin

By Zhang Guangtao  

Expert Opinion on Drug Discovery, Vol. 4, Iss. 9, 2009-09 ,pp. : 923-938

Informa Healthcare

Access to resources Recommend Favorite

In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug–Drug Interactions

By Karlgren Maria   Ahlin Gustav   Bergström Christel   Svensson Richard   Palm Johan   Artursson Per  

Pharmaceutical Research, Vol. 29, Iss. 2, 2012-02 ,pp. : 411-426

Springer Publishing Company

Access to resources Recommend Favorite

In silico analysis of antifungal peptides

By Soltani Saeed   Keymanesh Keykhosrow   Sardari Soroush  

Expert Opinion on Drug Discovery, Vol. 2, Iss. 6, 2007-06 ,pp. : 837-847

Informa Healthcare

Access to resources Recommend Favorite

Development of drugs for Epstein–Barr virus using high-throughput in silico virtual screening

By Li Ning   Thompson Scott   Jiang Hualiang   Lieberman Paul M   Luo Cheng  

Expert Opinion on Drug Discovery, Vol. 5, Iss. 12, 2010-12 ,pp. : 1189-1203

Informa Healthcare

Access to resources Recommend Favorite

Strategies for the generation, validation and application of in silico ADMET models in lead generation and optimization

By Gleeson Matthew Paul   Montanari Dino  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 8, Iss. 11, 2012-11 ,pp. : 1435-1446

Informa Healthcare

Access to resources Recommend Favorite